slidedeck.co

Capsida Biotherapeutics investor presentation, 2025

Cover slide of the Capsida Biotherapeutics 2025 investor presentation
Cover of Capsida Biotherapeutics' 2025 investor presentation.

The deck opens with a title slide and a forward-looking statements disclaimer, then frames the problem with first-generation genetic medicines: poor blood-brain barrier crossing, liver and dorsal root ganglia toxicity, narrow therapeutic windows, and risky invasive routes of delivery. It presents Capsida as a next-generation genetic medicines company with three wholly-owned programs in CNS and ophthalmology, followed by a pipeline timeline. Each program gets its own section covering the disease opportunity, preclinical non-human primate data on brain expression and liver and DRG detargeting, and the planned clinical study design. A platform section covers capsid engineering, manufacturing capabilities, and a facility overview. The closing sections list leadership and board members, funding history, and contact details, and the deck ends by repeating the company summary from the opening. Slides 8, 9 and 15 are worth studying for how the company charts preclinical expression and detargeting results against a benchmark, and slide 4 for how the pipeline timeline is laid out across programs.

Slides worth studying

Slide 4 of the Capsida Biotherapeutics investor presentation, reads "Clinical Stage Wholly-owned Programs First human POC by end of 2025 Disease / Target Preclinical IND-Enabling Phase 1/2 Key Catalysts STXBP1 Developmental and E". Table with columns: Disease / Target (text), Preclinical, IND-Enabling, Phase 1/2 (timeline stage column headers; bars sit under Preclinical/IND-Enabling), and Key Catalysts (timeline with year pills and quarter labels).
Slide 4: A Gantt-style table lays out each program's stages and key catalysts by quarter in one view, making the pipeline timeline easy to scan.
Slide 8 of the Capsida Biotherapeutics investor presentation, reads "STXBP1 Expression with CAP-002 in GLP Tox is Above Levels Required for Significant Correction of All Disease Phenotypes Brain Expression in NHPs in GLP Tox Stud". Left bar chart: vertical bars on log y-axis labelled WPRE copies/ ug RNA, ticks 10^3 to 10^8. X categories: AAV9* 2.5E13 (grey bar, about 1e4, error bar, one point), CAP-002 3.8E13 (light blue, about 2e6, three white dot
Slide 8: Bar charts of brain expression across three dose levels are annotated with full seizure correction and motor and cognitive correction thresholds, tying the data directly to efficacy claims.
Slide 15 of the Capsida Biotherapeutics investor presentation, reads "IV CAP-003 Achieves Superior GCase Protein Expression in GLP Tox Study Compared to ICM-delivered AAV9 Brain GCase Protein in NHP GLP Tox Study 40-60% decrease i". Vertical bar chart with error bars, logarithmic y-axis from 1 to 1000 (ticks 1, 10, 100, 1000), labelled 'Average Brain GCase protein (% increase over Vehicle)'. Bars approx.: ICM AAV9 ~20 (medium grey), CAP-003 IV 9.8E1
Slide 15: Compares the company's IV-delivered expression against an ICM-delivered AAV9 benchmark with labeled fold increases, using the same axis for a direct visual comparison.

Questions about this deck

What does the Capsida Biotherapeutics deck say about the timeline for its CAP-002 STXBP1-DEE program?

Slide 4 lists CAP-002 with an IND clearance received in 2025 Q2, Fast-track designation received, a first patient dosed in 2025 Q3, and first efficacy data in 2026 Q1. Slide 10 shows the same program with a projected first patient efficacy readout in the 2026 timeline.

How many slides does the Capsida Biotherapeutics corporate presentation have?

The deck has 33 slides. Slide 33 is the closing slide, titled 'Our Pipeline is Making the Impossible Possible,' and it lists the contact email and address.

What market opportunity does the Capsida Biotherapeutics deck give for CAP-003 in Parkinson's disease?

Slide 13 states that up to 15% of all PD cases equals about 330k patients in the US and Europe, that there are no approved GBA1 treatments and no PD disease modifying treatments, and that the opportunity has >$1B peak year sales. The slide also notes potential for expansion to idiopathic PD.

How much funding has Capsida Biotherapeutics raised according to its corporate presentation?

Slide 3 says the company has >$300M funding to date, including $50M Series A. Slide 31 shows the funding history, listing >$300M Funding to Date with rounds including $50M Series A, $90M CNS, $55M Ophthalmology, and $12M convertible note.

Details

  • Company: Capsida Biotherapeutics
  • Year: 2025
  • Type: Investor presentation
  • Industry: Biotechnology
  • Pages: 33

Review score: 7 out of 10, Effective

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

The deck follows a clear route: problem and solution table (2), company summary (3), pipeline (4), then a repeated block per program of opportunity, preclinical data and clinical plan. Charts on 8, 9 and 15 are well built, with action titles that state the finding, a benchmark bar in grey, callouts such as 207X and 10X, and reference bands. Weaknesses are consequential: many slides have very small footnotes, axis labels and study-design text (11, 20, 21, 28), and slide 4 puts small catalyst lists in a wide table. Slide 32 repeats slide 3 almost exactly and the closing does not drive to a clear takeaway, while the decorative body-figure dividers (5, 12, 22, 26, 29) add little.

Worth keeping: Keep the action-title charts with grey AAV9 benchmark, bracketed fold-change callouts and threshold bands (8, 9, 15), plus the consistent color-coding per program (blue CAP-002, green CAP-003, teal CAP-004) and the repeated opportunity/profile layout (6, 13, 23).

Most useful repair: Enlarge the footnotes, axis labels and trial-design text on slides 11, 20, 21 and 28, and tighten slide 4 so the catalysts read at a glance.

What would change the score: Replace the duplicate slide 32 with a closing summary that states the key milestones to watch, and cut or shrink the divider slides that carry only a stock figure.

Confidence high. 33 of 33 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-08. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (33 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

Capsida Biotherapeutics

Corporate Presentation

Aug 2025

This presentation is made solely for informational purposes and contains forward-looking statements based on current expectations and assumptions. These statements are not guarantees of future results.

The information contained herein is provided only as of the date on which this presentation is made and is subject to change.

This presentation does not constitute an offer or solicitation of any offer to sell or purchase any securities.

1

Visuals: Left: a 3D rendered translucent royal-blue human figure in profile, facing right, with a teal-green brain visible in the head and the heart, lungs and kidneys visible as lighter blue translucent organs. Clusters of dark grey-black glossy spheres (protein or capsid-like particles) form a column running down behind and beside the figure, with one smaller cluster of peach/orange-brown spheres floating in front of the face. The image bleeds off the left, top and bottom edges. Top right: the Capsida Biotherapeutics logo, with 'CAPSIDA' in teal capitals, 'BIOTHERAPEUTICS' in small spaced grey capitals below, and a faceted teal-to-green polygon/gem icon with a DNA helix strand across it. A thin light grey horizontal line runs from about x=43.7% to the right edge at y≈52.7%. A small image at the bottom left (about 4–9% x, 95–98% y) is a tiny footer mark.

Slide 2

Capsida: Working to Solve Challenges of Gen-1 Genetic Medicines

Starting in CNS and Ophthalmology with IP rights and applicability across all therapeutic areas

CNS Challenges

Capsida Solutions*

Crossing / the BBB

Limited ability to cross BBB; / < 1% neuronal transduction

>70% of neurons transduced in NHPs

Safety / Concerns

Liver and dorsal root ganglia (DRG) toxicity

>16x liver & >50x DRG detargeting; lower dosing

Patient / Populations

Narrow therapeutic index (TI) limits to / ultra-rare/rare diseases

Broader TI = more common diseases across ages

Route of / Administration

Direct injection to brain or CSF causes / significant risks and inconsistent expression

IV delivery avoids risks of invasive delivery and / allows for consistent expression

IV delivery increases risk of off-target effects / (esp. liver) and triggering immune response

Well-tolerated safety profile with no adverse / histopathological findings

*based on non-human primate (NHP) data

2

Visuals: Light grey (#F2F2F2) pill header with 'CNS Challenges' and a blue-to-cyan gradient pill header with 'Capsida Solutions*'. Below them a light grey rectangular panel and a blue gradient rectangular panel (dark blue #1F5F9E left to cyan #008CBA right), each split into five rows by thin light horizontal divider lines. Thin grey divider lines also run under the left row labels. A thin teal horizontal line spans the full width above the footer. The Capsida Therapeutics logo (small teal and blue geometric mark with wordmark) sits at bottom left.

Slide 3

Next-generation Genetic Medicines Company

Unlocking the full potential of gene therapy for all

Wholly-owned Pipeline

Fully-integrated Capabilities

External Validation

Two clinical programs in 2025

CAP-002: STXBP1-DEE

IND clearance

ODD granted

Fast Track granted

CAP-003: PD-GBA

IND clearance

Human POC in Q4

Third clinical program in 2026

CAP-004: Friedreich’s ataxia

» Capsid engineering

» Cargo optimization

» Clinical development

» In-house manufacturing

» Protected by expansive IP portfolio

Strategic partnerships

abbvie

1st AbbVie opt-in

($40M) achieved

Contract manufacturing

>$300M funding to date, including $50M Series A

VERSANT ventures

Westlake BioPartners

3

Visuals: Three outlined column panels with thin teal borders and blue-to-teal gradient header bands. Left column: three pill shapes (blue CAP-002 with three white check-circle icons, green CAP-003 with one check-circle and a white bullet dot, teal CAP-004). Centre column: » chevron bullets. Right column: abbvie wordmark logo in dark blue in a rounded outlined box with a » chevron and text, Eli Lilly red script logo in a rounded outlined box, CRISPR Therapeutics black-framed logo in a rounded box, KATE Therapeutics (A Novartis Company) logo in a rounded box with a green/black arrow mark, thin grey divider line above Contract manufacturing. Bottom: light grey rounded bar, Versant Ventures logo (teal V mark, grey text) and Westlake BioPartners logo (navy W mark, blue text) in white rounded boxes with light borders. Footer: thin teal horizontal line across the slide, Capsida Biotherapeutics logo with teal geometric mark at bottom-left.

Slide 4

Clinical Stage Wholly-owned Programs

First human POC by end of 2025

Disease / Target

Preclinical

IND-Enabling

Phase 1/2

Key Catalysts

STXBP1 Developmental and

Epileptic Encephalopathy

(STXBP1-DEE)

First-in-class CAP-002

2024 Q4 ODD received

2025 Q2 IND clearance received

Fast-track designation received

Q3 - First patient dosed

2026 Q1 - First efficacy data

Parkinson’s disease

associated with GBA

mutations

(PD-GBA)

Best-in-class CAP-003

2025 Q2 IND clearance received

Q3 - First patient dosed

Q4 - First biomarker data

2026 Q3 - First efficacy data (1 yr)

Friedreich’s ataxia

(FA)

Best-in-class CAP-004

2025 Q1 - IND-enabling studies ongoing

Q3 - Traditional & self-regulating cargo results

2026 2H - IND filing

Capsida is the first genetic medicines company with 2 FDA IND clearances for engineered IV-delivered

gene therapies that cross the blood-brain-barrier and detarget liver

4

Visuals: Table header bar: horizontal gradient from blue #0086B4 on the left to teal #00A79D on the right, with white bold column labels. Three rounded pill bars: a blue bar 'First-in-class CAP-002' (wide, spanning Preclinical to IND-Enabling), a green bar 'Best-in-class CAP-003' (same width), and a shorter teal bar 'Best-in-class CAP-004'. Grey rounded year chips (2024, 2025, 2026) sit beside the quarter labels. Blue circular check-mark icons mark ODD received, IND clearance received (twice) and Fast-track designation received. Thin grey horizontal divider lines separate the rows. A blue rounded rectangle banner holds white bold text. A thin teal horizontal line runs across the full width above the footer. The Capsida Therapeutics logo (blue wordmark with a teal geometric icon) sits at bottom-left.

Slide 5

CAP-002: STXBP1-DEE

STXBP1 Developmental and Epileptic

Encephalopathy

Visuals: Translucent 3D medical rendering of a human male figure in profile facing right, cropped at the waist and bleeding off the bottom and left edges. The body is a semi-transparent steel blue (#3A5A80) with visible internal organs (heart, lungs, kidneys, blood vessels) in lighter blue-grey. The brain is highlighted in muted teal-green (#5E8F85). Lighting is soft and even, with lighter translucent edges. Behind the figure's back and head, to the upper left, float clusters of dark grey glossy spheres (about #555555) forming protein or molecular structures. They sit against a white-to-pale-blue background and extend off the top edge. A thin light-blue horizontal line (#A9CCF0) crosses the right side at about y 80%.

Slide 6

STXBP1 Developmental and Epileptic Encephalopathy

Opportunity

DEE (like LGS and Dravet) with / no approved treatments

Seizures, developmental delays, / and motor impairment

~5,000 pediatric patients in US / and Europe

Genetic validation and potential / for FDA approval after Ph2

>$1B peak year sales

CAP-002

First and best in class IV-administered program

Industry-leading brain wide STXBP1 protein increases

Potential for correction of all phenotypes

Safety demonstrated in GLP-Toxicology study in NHPs, / including liver and DRGs

ODD and Fast Track granted

Successful IND clearance

SYNRGY Ph 1/2a clinical trial start up activities have initiated

6

Visuals: Left card: white rounded rectangle with a light grey outline and a light grey (#DCDDDE) header band; five light grey (#C4C5C8) circle bullets; thin grey divider lines between items (not after the last). Right card: pale blue (#E5F8FF) rounded rectangle with a blue outline and a blue (#0086B4) header band; six blue circular icons, each with a white check mark; thin pale grey-blue divider lines between items. Bottom banner: blue (#008EC0) rounded rectangle with a large corner radius. Thin teal horizontal line across the full width above the footer. Capsida Therapeutics logo at bottom left: small blue 'CAPSIDA' wordmark with a green and teal geometric shape and a script mark.

Slide 7

CAP-002 Restores Normal

STXBP1 Expression and

Neuronal Firing in Human

Knock Out Neurons*

Normal

#cell

0 20 40 60 80 100

Time (s)

CAP-002 restores neurons to normal firing

#cell

0 20 40 60 80 100

Time (s)

#cell

0 20 40 60 80 100

Time (s)

STXBP1 Knock Out*

STXBP1 Knock Out* with CAP-002

*in vitro data

Generated in collaboration with Neurospector, a CRO established by Matthijs Verhage’s laboratory at VUmc Research BV, part of Foundation Stichting Amsterdam UMC

7

Visuals: Three raster images of neuronal calcium-trace raster plots, each with grey line traces per cell and small red circle markers for detected firing peaks. Axes are #cell (vertical, unlabelled ticks) and Time (s) from 0 to 100 with ticks at 0, 20, 40, 60, 80, 100. Top-right 'Normal' plot: grey 4px border, synchronised vertical bands of peaks about every 8-10 s, about 13 bursts. Bottom-left STXBP1 Knock Out plot: red 4px border, dense irregular unsynchronised peaks scattered across all cells and times. Bottom-right Knock Out with CAP-002 plot: blue border with a rounded-top blue header tab, regular synchronised vertical bursts, about 14 bursts, closely resembling the Normal plot. A thin teal horizontal line spans the slide width above the footer. A Capsida Biotherapeutics logo (small teal and blue geometric cube/neuron icon with 'CAPSIDA' text) sits bottom-left.

Slide 8

STXBP1 Expression with CAP-002 in GLP Tox is Above Levels

Required for Significant Correction of All Disease Phenotypes

Brain Expression in NHPs in GLP Tox Study

Average Brain RNA

RNA in key ROIs

207X

WPRE copies/ ug RNA

10^8

10^7

10^6

10^5

10^4

10^3

AAV9*

CAP-002

CAP-002

CAP-002

2.5E13

3.8E13

5.9E13

7.4E13

WPRE copies/ ug RNA

10^8

10^7

10^6

10^5

Full Seizure Correction

Significant Motor and Cognitive Correction

3.8E13 vg/kg

5.9E13 vg/kg

7.4E13 vg/kg

Cortex

Hippocampus

Thalamus

1Murine data generated in collaboration with lab of Mingshan Xue, Baylor College of Medicine

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

8

Visuals: Left chart: bar chart titled by the pill 'Average Brain RNA'. The y axis is logarithmic, 10^3 to 10^8, labelled 'WPRE copies/ ug RNA'. Four bars: AAV9* 2.5E13 in light grey, about 1.1x10^4, with a small error bar; CAP-002 3.8E13 in light cyan, about 2.3x10^6; CAP-002 5.9E13 in mid blue, about 3.8x10^6; CAP-002 7.4E13 in dark teal-blue, about 4.5x10^6. Each CAP-002 bar has three white circle data points with black outlines and an upward error bar. A light blue dash-dot horizontal line sits at about 1.5x10^6 across the chart. A green bracket from the top of the AAV9 bar region up to the 3.8E13 bar is labelled '207X' in green bold. Right chart: grouped bar chart under the pill 'RNA in key ROIs'. The y axis is logarithmic, 10^5 to 10^8, labelled 'WPRE copies/ ug RNA'. Three groups, each with three bars for 3.8E13 (light cyan), 5.9E13 (mid blue) and 7.4E13 (dark teal) vg/kg. Cortex bars are about 1.8x10^6, 4x10^6 and 3.6x10^6. Hippocampus bars are about 7.5x10^5, 1.7x10^6 and 4.8x10^6. Thalamus bars are about 1.1x10^7, 1.2x10^7 and 5x10^6. Bars have black outlines, white dot points and error bars. Light blue dashed horizontal lines mark thresholds at about 8.5x10^5 over Cortex, 5x10^5 over Hippocampus and 1.3x10^6 over Thalamus. A legend at upper right has three small swatches for 3.8E13, 5.9E13 and 7.4E13 vg/kg. A light blue dashed legend line next to the labels 'Full Seizure Correction' and 'Significant Motor and Cognitive Correction'. A small Capsida Biotherapeutics logo with a teal geometric icon is at bottom left.

Slide 9

CAP-002 is Substantially Detargeted from Liver and DRGs / in NHPs in GLP Tox Compared to AAV9

Liver DNA in NHP GLP Tox Study

DRG RNA in NHP GLP Tox Study

10X

13X

WPRE copies/ ug DNA

WPRE copies/ ug RNA

10^9

10^8

10^7

10^6

10^5

10^8

10^7

10^6

10^5

10^4

AAV9 *

CAP-002

CAP-002

CAP-002

2.5E13

3.8E13

5.9E13

7.4E13

vg/kg

vg/kg

vg/kg

vg/kg

AAV9 *

CAP-002

CAP-002

CAP-002

2.5E13

3.8E13

5.9E13

7.4E13

vg/kg

vg/kg

vg/kg

vg/kg

Well-tolerated safety profile with no adverse histopathological findings

*Historical IV-delivered AAV9 2.5E13 vg/kg (non-STXBP1 cargo control)

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

9

Visuals: Two bar charts on a log scale, each with 4 bars and individual dots per animal (n=3). Left chart: Liver DNA, y-axis WPRE copies/ug DNA, 10^5 to 10^9. Bars: AAV9 2.5E13 vg/kg light grey, about 7E7, three filled black dots clustered at the top. CAP-002 3.8E13 bright cyan, about 7E6, open white dots at about 1.3E7, 5E6 and 2E6. CAP-002 5.9E13 mid blue, about 1.1E7, open dots about 1.4E7, 1.2E7 and 8E6. CAP-002 7.4E13 dark teal-blue, about 8E6, open dots about 1.7E7, 8E6 and 1.5E5. A green bracket from the AAV9 bar to the CAP-002 3.8E13 bar is labelled 10X. Right chart: DRG RNA, y-axis WPRE copies/ug RNA, 10^4 to 10^8. AAV9 grey bar about 3E6, black dots about 6E6, 1.7E6 and 9E5, with error bar. CAP-002 3.8E13 cyan bar about 2.4E5, open dots about 4.5E5, 2E5 and 8E4. CAP-002 5.9E13 blue bar about 4.5E5, open dots about 7E5, 4.5E5 and 2.2E5. CAP-002 7.4E13 dark blue bar about 6.8E5, open dots about 1E6, 7E5 and 4.5E5. A green bracket from the AAV9 bar to the CAP-002 3.8E13 bar is labelled 13X. The bars have thin black outlines and the axes are black, with tick marks. Asterisks follow AAV9 on both x-axes. The Capsida Biotherapeutics logo, a teal geometric gem with blue text, sits bottom left. A thin teal horizontal line spans the slide above the footer.

Slide 10

CAP-002 Phase 1/2a SYNRGY Study

Potential for approval after Phase 2 study

Clinical Ph1/2 / Planning

Population

» 18 months – 7 years

» Potential expansion / to broader ages

» Ph1: 6 patients

Key Measurements

» Safety

» Motor, language, neurocognitive, / seizure, and EEG

» Clinical scales consistent with / STARR natural history study

Plan to leverage / Fast Track, ODD, and / other designations to / accelerate approval

2025

2026

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

CAP-002 / (STXBP1-DEE) / Program / Overview

IND-Enabling

Clinical Ph1/2a

IND Clearance

Fast Track Granted

Projected 1st Patient Dosed

Projected 1st Patient Efficacy

Projected FDA Meeting

For more information about the SYNRGY trial, please visit www.clinicaltrials.gov and search for NCT06983158

EEG = electroencephalogram; STARR = STXBP1 Clinical Trial Ready

10

Visuals: Gantt-style timeline: teal header bar with years 2025 (Q1–Q4) and 2026 (Q1–Q4), a grey quarter row, vertical thin grey gridlines between quarters with a light-blue line at the 2025/2026 boundary. Row label 'CAP-002 (STXBP1-DEE) Program Overview' in a grey box. A light-blue pill 'IND-Enabling' spans 2025 Q1 and a longer light-blue pill 'Clinical Ph1/2a' spans 2025 Q2 to 2026 Q4. Milestones: teal six-point star plus black checkmark at 'IND Clearance' (2025 Q2); teal diamond plus checkmark at 'Fast Track Granted' (2025 Q2–Q3); star at end of 'Projected 1st Patient Dosed' (2025 Q3) with a thin teal arrow pointing right to about the start of 2026 Q1; star at end of 'Projected 1st Patient Efficacy' (start of 2026 Q1) with a teal arrow to about 2026 Q3; teal diamond before 'Projected FDA Meeting' (2026 Q3). The Capsida Biotherapeutics logo (teal text with a green and teal geometric mark) sits at bottom left.

Slide 11

CAP-002 Phase 1/2a SYNRGY Study (NCT06983158)

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

ClinicalTrials.gov ID NCT06983158

Sponsor Capsida Biotherapeutics, Inc.

Ph1

Dose escalation

N=6

Ph2a (single dose)

N=6

Primary endpoints:

• Safety

Clinician reported secondary endpoints:

• Bayley Scales of Infant & Toddler Development

• Gross Motor Function

• STXBP1-Clinical Severity Assessment-Clinician

• Peabody Developmental Motor Scales

Caregiver reported secondary endpoints

“This is the first potentially disease-modifying treatment for STXBP1-DEE, and we are excited to be part of the SYNRGY clinical trial,”

- Ingo Helbig, M.D., Pediatric Neurologist and Director of Clinical Research at the Center for Epilepsy and Neurodevelopmental Disorders (ENDD) at Children’s Hospital of Philadelphia (CHOP), and paid consultant to Capsida¹

“STXBP1-related disorders present devastating challenges in communication, development, motor function and seizures. We are in dire need of targeted therapies that can improve the lives and functioning of our children and families,”

- Charlene Son Rigby, STXBP1 Foundation President & Founder¹

¹ Capsida May 12, 2025 press release

See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints

11

Visuals: A screenshot image of the ClinicalTrials.gov header (grey-black condensed bold title in two lines, dark blue labels 'ClinicalTrials.gov ID' and 'Sponsor', each followed by a dark navy circular info icon, with the values in dark grey condensed text). Left: a white rounded rectangle with a teal (#0086B4) outline containing two teal rounded rectangles with dark navy outlines (upper taller 'Ph1 Dose escalation N=6', lower 'Ph2a (single dose) N=6'). Right: a teal rounded-corner rectangle with white text. Two pale blue (#DCEAF7) rectangles with soft drop shadows holding the quotes. A thin teal horizontal line across the slide above the footer. Small Capsida Biotherapeutics logo (blue wordmark 'CAPSIDA' with a teal/green geometric polyhedron icon and a faint script mark) at bottom left.

Slide 12

CAP-003: PD-GBA

Parkinson’s disease associated

with GBA mutations

Visuals: Semi-transparent 3D medical illustration of a male torso and head in profile facing right, rendered in translucent steel blue. The brain is tinted muted green. Internal organs are visible: heart, lungs, kidneys and blood vessels. The figure is cropped at the waist by the bottom edge, with lighting soft and even. Behind the shoulder and head at upper left, clusters of dark grey glossy spheres form protein or molecular aggregates, some in strands and some in clumps, partly cropped by the top and left edges. A thin pale blue horizontal line crosses the right side at about 80% height.

Slide 13

Parkinson’s Disease Associated with GBA Mutations

Opportunity

Up to 15% of all PD cases = ~330k

patients in US and Europe

No approved GBA1 treatments

and no PD disease modifying

treatments

>$1B peak year sales

Potential for expansion to

idiopathic PD

CAP-003

Best in class IV-administered program

Industry-leading brainwide GCase enzyme elevation

Potential for significant disease modification

Safety demonstrated in GLP-Toxicology study in NHPs,

including liver and DRGs

Successful IND clearance

NHP = non-human primate

13

Visuals: Left card: white body with light grey outline and rounded corners, grey header band, four light grey circular bullet markers, thin grey divider lines between items. Right card: mint green body with teal outline and rounded corners, green header band, five teal filled circles with white check marks, thin grey-green divider lines between items. A thin teal horizontal line runs across the full width above the footer. Bottom left: small Capsida Therapeutics logo (blue wordmark 'CAPSIDA' with teal and blue geometric polyhedron mark).

Slide 14

IV-delivered CAP-003 Achieves Superior RNA Expression

Compared to ICM-delivered AAV9 in NHPs

Brain RNA in NHP GLP Tox Study

AAV9 2E11 vg/g ICM¹

CAP-003 3.1E13 vg/kg IV

CAP-003 9.8E12 vg/kg IV

CAP-003 5.0E13 vg/kg IV

WPRE copies/µg RNA

10⁸

10⁷

10⁶

10⁵

10⁴

10³

10²

181X

5888X

Frontal Cortex

Putamen

¹AAV9 ICM data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but / different therapeutic cargo; no protein or %neuron comparison possible

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

14

Visuals: Grouped bar chart on a log scale in a card with a green header band 'Brain RNA in NHP GLP Tox Study'. Y axis 'WPRE copies/µg RNA' from 10^2 to 10^8 with ticks at each decade; X axis has two groups, Frontal Cortex and Putamen, with a tick under each group. Legend (2x2) of square swatches: grey AAV9 2E11 vg/g ICM¹, pale mint CAP-003 9.8E12 vg/kg IV, medium green CAP-003 3.1E13 vg/kg IV, dark green CAP-003 5.0E13 vg/kg IV. Frontal Cortex bars: grey about 1.7x10^4 (error cap about 2.7x10^4), pale mint about 4.8x10^5 (cap about 5.5x10^5), medium green about 3x10^6 (cap about 4x10^6), dark green about 1.2x10^7 (cap about 1.8x10^7). Putamen bars: grey about 5.5x10^2 with no error bar, pale mint about 3x10^5 (cap about 3.8x10^5), medium green about 3.5x10^6 (cap about 4.5x10^6), dark green about 4x10^6 (cap about 6.5x10^6). Green bracket lines with green labels '181X' above Frontal Cortex and '5888X' above Putamen link the grey bar to the medium-green bar, ending in a downward arrow tick over the medium-green bar. Error bars are black T-caps. Capsida Biotherapeutics logo (blue text with teal geometric polyhedron icon) bottom left. Thin teal horizontal line across the slide above the footer.

Slide 15

IV CAP-003 Achieves Superior GCase Protein Expression in

GLP Tox Study Compared to ICM-delivered AAV9

Brain GCase Protein in NHP GLP Tox Study

Average Brain GCase protein

(% increase over Vehicle)

1000

100

10

1

~20%

48%

141%

415%

ICM AAV9²

8E10 vg/g brain

CAP-003 IV

9.8E12 vg/kg

CAP-003 IV

3.1E13 vg/kg

CAP-003 IV

5E13 vg/kg

40-60% decrease in

GCase bulk protein¹

¹ Sanz Munoz et al., 2021 Decrease in GCase bulk protein in post-mortem brain tissues compared to healthy individuals

² ICM AAV9 reported by Prevail (Source: 2019 S1 filing) in their non-clinical NHP studies (~20% increase across cortex,

hippocampus, midbrain 6 months after administration)

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

15

Visuals: Bar chart on a log scale inside a white card with a thin teal outline and a green rounded-top header bar reading 'Brain GCase Protein in NHP GLP Tox Study'. Y axis is a black line with ticks at 1, 10, 100 and 1000 (log scale), titled 'Average Brain GCase protein (% increase over Vehicle)' (rotated). X axis is a thick black line with four ticks. Four bars: grey (#A0A0A4) ICM AAV9 8E10 vg/g brain, no error bar, top about 20; very light mint (#B4F8DF) CAP-003 IV 9.8E12 vg/kg, top about 48 with a small error bar to about 55; medium mint green (#75DEAB) CAP-003 IV 3.1E13 vg/kg, top about 141 with error bar to about 170; dark green (#208856) CAP-003 IV 5E13 vg/kg, top about 415 with error bar to about 590. Each bar has a light grey (#DADADA) label box near its base with bold value: ~20%, 48%, 141%, 415%. A light grey horizontal band (#D4D4D4) spans the plot between about 40 and 60 on the axis, with the annotation '40-60% decrease in GCase bulk protein¹' to its right. A thin teal horizontal line runs across the full slide width above the footer. The Capsida Biotherapeutics logo (small blue text with a teal geometric icon) sits at bottom left. No legend.

Slide 16

CAP-003 Exceeds Efficacy Threshold for Normalizing GCase

Activity in Patients in NHP GLP Tox Study

Brain GCase Activity in NHP GLP Tox Study

1000

100

10

1

Average Brain GCase activity

(% increase over Vehicle)

10%

86%

206%

30% therapeutic threshold¹

(based on human post-mortem data)

CAP-003

9.8E12 vg/kg

CAP-003

3.1E13 vg/kg

CAP-003

5E13 vg/kg

¹Leyns et al., 2023. Post-mortem studies demonstrate an approximate 30% GCase activity deficit in patients compared to

healthy individuals

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

16

Visuals: Bar chart in a white panel with a thin teal outline and a green (#2BB673) rounded-top header band reading 'Brain GCase Activity in NHP GLP Tox Study'. Log-scale y-axis from 1 to 1000 with ticks at 1, 10, 100 and 1000, titled 'Average Brain GCase activity (% increase over Vehicle)' (rotated). Three vertical bars on a black x-axis with tick marks below each bar. Bar 1, CAP-003 9.8E12 vg/kg, is pale mint (#D1F4E3), height about 10, with a label box '10%' and a small error bar up to about 11. Bar 2, CAP-003 3.1E13 vg/kg, is medium mint green (#75DEAB), height about 86, labelled '86%', error bar up to about 115. Bar 3, CAP-003 5E13 vg/kg, is dark green (#208856), height about 206, labelled '206%', error bar up to about 290. Each percent label sits in a light grey (#D9D9D9) rectangle near the bar base. A black dashed horizontal line at about 30 crosses the chart and extends right of the bars to the label '30% therapeutic threshold¹ (based on human post-mortem data)'. A small Capsida Biotherapeutics logo with a teal/blue polyhedral mark sits at bottom-left. A thin teal horizontal line runs full width above the footer.

Slide 17

CAP-003 Significantly Increases GCase in CSF in GLP Tox

Study Validating Use as Clinical Biomarker

GCase Protein in CSF in NHP GLP Tox Study

Correlation of CSF GCase Protein

& Brain GCase Activity

GCase protein in CSF

(% increase over Vehicle)

10000

1000

100

10

1

72%

479%

984%

CAP-003

9.8E12 vg/kg

CAP-003

3.1E13 vg/kg

CAP-003

5E13 vg/kg

10

5

0

-5

r = 0.986

p < 0.0001

GCase protein

CSF (ng/mg)

0.2

0.4

0.6

0.8

1.0

Average Brain GCase activity

(mU/g protein)

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

17

Visuals: Left panel: log-scale bar chart with three bars and error bars, y-axis 1 to 10000 (ticks 1, 10, 100, 1000, 10000), black axis lines, y-axis title 'GCase protein in CSF (% increase over Vehicle)'. Bars: CAP-003 9.8E12 vg/kg pale mint (#D1F4E3) at about 72, labelled 72% in a light grey box; CAP-003 3.1E13 vg/kg medium mint green (#75DEAB) at about 479, labelled 479%; CAP-003 5E13 vg/kg dark green (#208856) at about 984, labelled 984%. Error bars extend to about 110, 580 and 1400 respectively. Tick marks under each bar. Right panel: scatter plot with regression line and dotted confidence band, x-axis Average Brain GCase activity (mU/g protein) 0.2 to 1.0 with ticks at 0.2, 0.4, 0.6, 0.8, 1.0; y-axis GCase protein CSF (ng/mg) from -5 to 10 with ticks -5, 0, 5, 10. About 12 black dots, clustered near (0.2–0.35, 0–2) and others at about (0.34, 2.1), (0.41, 3.8), (0.56, 3.8), (0.82, 7.4), (0.91, 9.0). A boxed black-outline text 'r = 0.986 / p < 0.0001' sits at top left of the plot. Teal horizontal rule near the bottom of the slide. Capsida Biotherapeutics logo (small blue text with a teal geometric icon) at bottom left.

Slide 18

Decreased GluSph Levels in Plasma Confirm Target

Engagement in GLP Tox Study in Healthy NHPs

Plasma GluSph in NHP GLP Tox Study

-29%

-11%

-32%

0

-10

-20

-30

-40

-50

GluSph in plasma

(% change from Vehicle)

CAP-003

9.8E12 vg/kg

CAP-003

3.1E13 vg/kg

CAP-003

5E13 vg/kg

GluSph = Glucosylsphingosine

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

18

Visuals: A bar chart in a white panel with a thin teal outline (about x 17-84%, y 22-90%) and a rounded-top green header band reading 'Plasma GluSph in NHP GLP Tox Study'. Chart is titled by that band. Y axis: 'GluSph in plasma (% change from Vehicle)', range 0 at top to -50 at bottom, ticks every 10 (0, -10, -20, -30, -40, -50), thick black axis lines. The x axis is drawn at the bottom (-50) with three tick marks. Three downward bars hang from the 0 line at the top, each with a downward error bar with a cap. Bar 1: CAP-003 9.8E12 vg/kg, pale mint (#D1F4E3), value -29%, error bar to about -41. Bar 2: CAP-003 3.1E13 vg/kg, medium mint green (#75DEAB), value -11%, error bar to about -25. Bar 3: CAP-003 5E13 vg/kg, dark green (#208856), value -32%, error bar to about -39. Above each bar is a light grey (#D9D9D9) rectangular label box with its percentage in bold black. No legend. A thin teal horizontal rule spans the full slide width above the footer. A small CAPSIDA Therapeutics logo (teal text with a teal and green geometric polyhedron icon) at bottom-left.

Slide 19

GLP Tox Data Demonstrate CAP-003 is Substantially Detargeted

from Liver and DRGs in NHPs Compared to AAV9

Liver DNA

DRG RNA

18X lower at double the dose

3X lower at double the dose

DNA biodistribution

(WPRE copies/µg DNA)

10^8

10^7

10^6

RNA biodistribution

(WPRE copies/µg RNA)

10^7

10^6

10^5

AAV9*

2.5E13 vg/kg

CAP-003

5E13 vg/kg

AAV9*

2.5E13 vg/kg

CAP-003

5E13 vg/kg

Well-tolerated safety profile with no adverse histopathological findings

*Historical IV-delivered AAV9 2.5E13 vg/kg (non-GBA cargo control)

NHP = non-human primate

GLP Tox Study

In-life: 3 months

Species: Cynomolgus macaques (n=3/grp)

19

Visuals: Two bar charts on log scales, each in a white panel with thin teal outline and green rounded-top header. Left chart (Liver DNA): y-axis 10^6 to 10^8, label 'DNA biodistribution (WPRE copies/µg DNA)'. Grey bar AAV9* 2.5E13 vg/kg reaches about 7x10^7 with a tiny error bar. Dark green bar CAP-003 5E13 vg/kg reaches about 4x10^6 with an upper error bar to about 5x10^6. Green bracket line from the top of the AAV9 bar down to the CAP-003 bar, annotated '18X lower at double the dose'. Right chart (DRG RNA): y-axis 10^5 to 10^7, label 'RNA biodistribution (WPRE copies/µg RNA)'. Grey AAV9* bar reaches about 3x10^6 with an error bar up to about 5x10^6. Dark green CAP-003 bar reaches about 9x10^5 with an error bar to about 1.1x10^6. Green bracket annotated '3X lower at double the dose'. Black axes with tick marks. A blue-to-teal gradient rounded banner holds white text. The Capsida Biotherapeutics logo (teal text with a hexagonal icon) sits at bottom left. A thin teal horizontal line spans the full width above the footer.

Slide 20

CAP-003 (PD-GBA) Phase 1/2 Clinical Plan

Clinical Ph1/2

Planning

Population

» Ages 21-75 years

» PD Hoehn & Yahr

Stage 1-3

» Ph1: 6 patients

Key Measurements

» Safety

» Biomarkers (e.g., GCase, GluSph, & GluCer)

» 1 & 2-year efficacy (e.g., MDS-UPDRS, cognition, etc.)

2025

2026

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

IND-Enabling

Clinical Ph1/2

CAP-003

(PD-GBA)

Program

Overview

IND Clearance

Projected 1st Patient Dosed

Projected 1st Patient Biomarkers

Projected 1st Patient Efficacy (1 yr)

Projected FDA Meeting

For more information about the Phase 1/2 trial, please visit www.clinicaltrials.gov and search for NCT07011771

GluSph = glucosylsphingosine; GluCer = glucosylceramide;

MDS-UPDRS = Unified Parkinson's Disease Rating Scale

20

Visuals: Gantt timeline with 2025 and 2026 headers and Q1-Q4 each, with faint vertical grey quarter dividers and a light teal divider at the year boundary. Mint pill bars: IND-Enabling spans 2025 Q1 to mid Q2, Clinical Ph1/2 spans from late Q2 2025 to end of 2026 Q4. Green six-pointed star markers precede the milestones. IND Clearance has a star and a black checkmark at about Q2/Q3 2025. Projected 1st Patient Dosed has a star at about 2025 Q3 and a green arrow running to about 2026 Q1. Projected 1st Patient Biomarkers has a star at about 2025 Q4 and an arrow to about 2026 Q2. Projected 1st Patient Efficacy (1 yr) has a star at about 2026 Q3 and an arrow to the right end of 2026 Q4. Projected FDA Meeting has a green diamond at about 2026 Q2/Q3. Capsida Biotherapeutics logo at bottom-left, with teal text and a teal and green geometric mark. Thin teal horizontal line above the footer.

Slide 21

CAP-003 Phase 1/2 Study (NCT07011771)

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

ClinicalTrials.gov ID NCT07011771

Sponsor Capsida Biotherapeutics, Inc.

Ph1

Dose escalation

N=6

Ph2 (single dose)

N=25

Primary endpoints:

• Safety

Efficacy (secondary endpoints)

• CSF and plasma glucosylsphingosine (GluSph) biomarker change

• CSF and plasma β-Glucocerebrosidase (GCase) biomarker change

• MDS-UPDRS disease rating change

“We recognize the urgency for new treatment approaches, so we are working diligently to initiate the Phase 1/2 clinical trial for CAP-003 with the aim of dosing the first patient in the third quarter of this year,” –

Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics

See clinicaltrials.gov for full list of clinician & caregiver secondary endpoints

21

Visuals: Left: a white rounded rectangle with a green (#2BB673) outline containing two green rounded rectangles with dark navy outlines (Ph1 Dose escalation N=6, Ph2 single dose N=25). Right: a solid green rounded rectangle with white bullet text. A pale mint quote box with a subtle drop shadow. Two small navy circled 'i' info icons next to the labels. A thin teal horizontal line across the slide above the footer. A Capsida Biotherapeutics logo at bottom left (small teal geometric emblem with blue 'CAPSIDA' wordmark).

Slide 22

CAP-004: FA

Friedreich’s ataxia

Visuals: Full-slide pale gradient background. On the left, a 3D medical illustration of a translucent blue-grey human torso and head in profile facing right, cropped at the waist by the bottom edge. Inside it are visible organs: a green-tinted brain in the head, lungs, a heart, kidneys and vessels, in muted blues. Soft studio lighting with a transparent, glassy look. Behind the figure's shoulder and upper left are clusters of dark grey metallic spheres forming molecular or protein structures that trail diagonally from the top centre-left down to the shoulder. They fade into white at the left. A thin light-blue horizontal line extends from the torso to the right edge.

Slide 23

Friedreich’s Ataxia

Opportunity

CNS, cardiac, and sensory / manifestations

~5,000 patients in the US and / 15,000 worldwide

Genetic validation and potential / for FDA approval after Ph2

>$1B peak year sales

CAP-004

Best in class IV-administered program

Industry-leading frataxin protein expression in all / relevant tissues

Potential for correction of CNS, cardiac, and / sensory manifestations

Safety demonstrated in NHPs, including liver and DRGs

IND-enabling studies ongoing, incl. self-regulating cargo

2H 2026 IND Filing

23

Visuals: Left card: white body with light grey outline, rounded corners, grey header band, four grey circle bullets, thin grey divider lines between items. Right card: pale cyan body with thin green outline and rounded corners, teal header band, five green filled circles with white checkmarks and one empty green outlined circle for the last item, thin light-teal divider lines between items. Thin teal horizontal line across the full width near the bottom. Capsida Biotherapeutics logo (teal text with a teal and green geometric polyhedron mark and a script wordmark) at bottom-left.

Slide 24

IV CAP-004 Achieves Therapeutically Meaningful RNA Expression

Levels in Key FA Tissues While Detargeting Liver

Brain FXN in NHPs

Spinal Cord & Sensory

Neuron FXN in NHPs

Liver FXN in NHPs

>750X

>600X

>13X

<6X

>14X

WPRE copies/ug RNA

10^8

10^7

10^6

10^5

10^4

10^3

Motor Cortex

Cerebellum

SC

DRG

Retina

Liver

AAV9 2.5E13 vg/kg1

CAP-004 2.5E13 vg/kg

FXN = Frataxin

1 AAV9 data generated from past Capsida study with same expression cassette (promoter, regulatory elements, etc.) but different therapeutic cargo

24

Visuals: Three log-scale bar charts, each in a white panel with a thin teal outline and a teal header with rounded top corners. All three y-axes read 'WPRE copies/ug RNA' with ticks 10^3, 10^4, 10^5, 10^6, 10^7, 10^8. Grey bars are AAV9 and teal bars are CAP-004, with black error bars. Values below are estimates. Chart 1, Brain FXN in NHPs, x categories Motor Cortex and Cerebellum. Motor Cortex: AAV9 about 8x10^3 (error about 5x10^3 to 1.1x10^4), CAP-004 about 6x10^6 (error about 1.5x10^6 to 1.1x10^7). Cerebellum: AAV9 about 1.4x10^4 (error about 1x10^4 to 2x10^4), CAP-004 about 8x10^6 (error about 6x10^6 to 1.1x10^7). Teal bracket lines link the grey and teal bars of each category, labelled >750X over Motor Cortex and >600X over Cerebellum. Chart 2, Spinal Cord & Sensory Neuron FXN in NHPs, categories SC, DRG, Retina. SC: AAV9 about 6x10^5 (error about 2x10^5 to 1x10^6), CAP-004 about 7x10^6 (error about 3x10^6 to 1.2x10^7). DRG: AAV9 about 3x10^6 (error about 1.5x10^6 to 5x10^6), CAP-004 about 5x10^5 (error about 3x10^5 to 7x10^5). Retina: no AAV9 bar, CAP-004 about 1.7x10^6 (error about 1.3x10^6 to 2.2x10^6). Teal brackets are labelled >13X over SC and <6X over DRG. Chart 3, Liver FXN in NHPs, one category Liver. AAV9 about 4.5x10^5 (error about 2.5x10^5 to 6x10^5), CAP-004 about 3x10^4 (error about 2x10^4 to 4x10^4). A teal bracket labelled >14X joins the two bars. Legend: grey square labelled AAV9 2.5E13 vg/kg with superscript 1, teal square labelled CAP-004 2.5E13 vg/kg. A thin teal horizontal line spans the slide above the footer. The Capsida Biotherapeutics logo, with a teal and blue faceted gem icon, sits at bottom left.

Slide 25

27% Average Transduction of Left Ventricle with CAP-004

Results in >70% Increase in FXN Expression in Heart

Left Ventricle %HA Positive Area in NHPs

Cardiac FXN protein levels increase in NHPs

CAP-004 2.5E13 vg/kg

Untreated

CAP-004 2.5E13 vg/kg

27%

70%

50

40

30

20

10

0

% Area

1000

100

10

1

ng FXN per mg of protein

25

Visuals: Left panel: bar chart titled 'Left Ventricle %HA Positive Area in NHPs'. Y axis '% Area' from 0 to 50 with ticks every 10. One solid teal bar for CAP-004 2.5E13 vg/kg reaching about 27 (label '27%' in bold black above it). Error bar upper cap at about 36. Three black dots at about 38, 34.5 and 7.5. Legend: teal square with 'CAP-004 2.5E13 vg/kg'. Right panel: bar chart titled 'Cardiac FXN protein levels increase in NHPs'. Y axis 'ng FXN per mg of protein', log scale from 1 to 1000 with ticks at 1, 10, 100, 1000. Two bars: Untreated is white with teal outline, height about 60; CAP-004 2.5E13 vg/kg is solid teal, height about 100. Black dots: one at about 60 on the untreated bar, three on the CAP-004 bar at about 130, 110 and 65. Small error bar cap on the teal bar at about 120. A black bracket joins the two bars, with '70%' in bold black above it. Legend: white square with teal outline 'Untreated' and teal square 'CAP-004 2.5E13 vg/kg'. Thin teal horizontal line at the bottom. Capsida Biotherapeutics logo (small teal text with a green-teal geometric polyhedron icon) at bottom left.

Slide 26

Platform and Capabilities

Visuals: A 3D medical-style illustration of a male figure in profile, facing right, torso cropped at the bottom edge. The body is rendered as a translucent steel-blue (#3A5578) shape with visible internal organs: a green-grey brain (#5B7F78) in the head, heart, lungs, kidneys and blood vessels in lighter blue. Dark grey glossy spheres form clusters of protein or molecular structures that float behind the shoulder and head at the upper left, with a few chains of beads. The figure fades into the pale background with soft edges. A thin light-blue line (#A9CBEE, about 1px) runs horizontally at y≈80% from x≈38% to the right edge. No logos.

Slide 27

Capsida – Uniquely Positioned to Lead Gene Therapy

Capsid Engineering Scale

Fully industrialized and / roboticized platform

Screening capabilities across cell / types in NHPs and human cells

CNS Tropism

>99% specific to neurons

>70% neurons transduced

Broad IP capsids and / capsid/cargo

Peripheral Detargeting

>16x liver & >50x DRG detargeted

Superior off-target safety profile

Broad IP protecting detargeting

Therapeutic Expression

Expression in NHPs with / potential for full disease / correction

Industry leading expression / levels across pipeline programs

Clinical Translatability

Identified/patented novel human / receptor with complete homology / in NHPs and humans

Validated expression in NHPs / including primates >20 years old

Manufacturability

In-house process development / and GMP manufacturing

Productivity surpassing AAV9

Quality specifications > FDA / requirements

Only Capsida has created all the capabilities and results needed to / deliver on the promise of gene therapy

27

Visuals: Six cards: each has a header with rounded top corners filled with a horizontal gradient from blue (#0088BB) on the left to teal-green (#00AA9E) on the right, and a white body with a 1px teal outline. Thin light-gray divider lines separate statements within each card. A wide rounded-rectangle banner with the same blue-to-teal gradient spans the lower part. A thin teal horizontal line spans the full slide width above the footer. The Capsida Biotherapeutics logo (blue 'CAPSIDA' wordmark with a small teal and green hexagonal/geometric mark with script text) is at the bottom left.

Slide 28

In-house Process & Analytical Development and cGMP Manufacturing

Enables Capsida to control quality, timelines, and costs

Vector

Production

Rapid production of engineered capsids for preclinical studies

Process &

Analytical

Development

Conduct manufacturability assessment in HEK293 suspension process

Up to 50 L bioreactor scale

Develop and optimize key analytical assays

cGMP

Manufacturing

15,000 ft2 cGMP Manufacturing Facility

Leverages single use systems

200L bioreactor scale with ability to significantly expand capacity

Finish – fill operations

Unidirectional flow

In-house QC capabilities for product release

Modular clean rooms

Excellent yields and quality specifications at or above FDA standards

28

Visuals: Three small photographs in the middle column. Top: a woman in a blue lab coat working at a benchtop centrifuge in a lab with shelves. Middle: a man in a blue lab coat working beside a red bioreactor/incubator unit in a lab. Bottom: two people in white cleanroom suits, hoods and green gloves working at a stainless steel bioreactor in a cleanroom. Thin teal horizontal divider lines at about y 33.5%, 53.5% and 81%. Light gray thin lines between bullet rows. A rounded rectangle banner with blue-to-green horizontal gradient. A thin teal footer line across the full width. Capsida Biotherapeutics logo at bottom left (blue wordmark with teal leaf/triangle icon).

Slide 29

Corporate & Finance

Visuals: Rendered 3D translucent human torso in profile facing right, in steel blue (#2F4A6E) with a visible green-grey brain (#5F8B80) in the head, heart, lungs, kidneys and vessels showing through the body. The figure is cropped at the waist and the left arm is cut off at the slide edge. Behind the head and shoulders, clusters of grey-black glossy spheres form molecular or protein strands, rising diagonally from the shoulder to the top edge of the slide. They are lit softly, with a white fade on the left. A thin light-blue horizontal line (#A9CBEF, about 1px) extends from the figure's torso to the right edge.

Slide 30

Leadership Team and Board of Directors

Decades of Industry Experience and Drug Development Expertise

Leadership

Board Members

Peter Anastasiou

Chief Executive Officer

Nicholas Flytzanis,

PhD

Founder, Chief Research

and Innovation Officer

Swati Tole, MD

Chief Medical

Officer

Clare Ozawa,

PhD

Beth Seidenberg,

MD

Viviana Gradinaru,

PhD

Founder

Julie Hakim

Chief Financial Officer

Bethany Mancilla

Chief Business Officer

Rob Murphy

Chief Manufacturing

and Quality Officer

Rita Balice-Gordon,

PhD

CEO, Muna Tx

Frank Verwiel,

MD

Chairman, Intellia

Peter Anastasiou

Chief Executive Officer

30

Visuals: Two horizontal pill-shaped gradient banners (Leadership: teal-blue #0088B8 to green-teal #00A79D; Board Members: darker blue #2060A0 to light blue #0088C0). Twelve rounded-corner square portrait photos on light grey #F2F2F2 backgrounds, each a professional headshot of a person from the chest up, on a neutral grey backdrop. Leadership row 1: bald smiling man in grey blazer and light blue shirt; bearded dark-haired man in dark jacket; smiling woman with long black hair, dark navy top. Leadership row 2: woman with short blond hair and green top; woman with long grey-blonde hair in light blue top; older man with dark grey hair in navy jacket and light blue shirt. Board row 1: woman with black bob hair; woman with long wavy brown-grey hair in black top; woman with brown shoulder-length hair in cream top. Board row 2: woman with dark brown hair in cream top; man in dark suit and white shirt with short hair; bald smiling man in grey blazer. Small white rounded-rectangle logo chips with thin grey border beneath each person: Peter Anastasiou (CEO): Lundbeck with red starfish, Lilly script logo. Nicholas Flytzanis: Caltech. Swati Tole: Genentech. Clare Ozawa: Versant Ventures, Novartis. Beth Seidenberg: Westlake BioPartners, Kleiner Perkins. Viviana Gradinaru: Caltech. Julie Hakim: Lundbeck, Sequoia Vaccines. Bethany Mancilla: Amgen, Micromet. Rob Murphy: Amgen. Rita Balice-Gordon: Muna Therapeutics, Sanofi. Frank Verwiel: Avexis, Intellia Therapeutics. Peter Anastasiou (second): Lundbeck, Lilly. Thin teal horizontal line near the bottom; Capsida Biotherapeutics logo with teal-green geometric mark at bottom left.

Slide 31

>$300M Funding to Date

2019

2021

2023

2025

$50M Series A

CNS $90M

CNS $55M

Ophthalmology $70M

Contract manufacturing

$12M convertible note

AbbVie opt-in ($40M)

Potential additional milestones

Series B (TBD)

31

Visuals: Four gradient pill labels (blue to teal; the 2025 pill is a darker blue) on a thin teal horizontal line. White rounded-corner logo cards with light grey borders. 2019 column: Versant Ventures logo (grey-teal V mark with VERSANT ventures wordmark), Westlake BioPartners logo (blue wave mark with blue text). 2021 column: AbbVie logo (navy lowercase wordmark). 2023 column: Lilly logo (red script), AbbVie logo, KATE Therapeutics logo (green and grey chevron mark, dark KATE lettering, 'A Novartis Company' tagline), NEURO.VC logo (dark navy bold condensed text with a small box). 2025 column, inside a pale blue rounded rectangle with a teal outline: AbbVie logo, a second AbbVie logo, Lilly logo, and Capsida Biotherapeutics logo (blue CAPSIDA text with teal and green geometric mark). A small Capsida logo sits bottom-left in the footer. A thin teal line spans the full width above the footer.

Slide 32

Next-generation Genetic Medicines Company

Unlocking the full potential of gene therapy for all

Wholly-owned Pipeline

Fully-integrated Capabilities

External Validation

Two clinical programs in 2025

CAP-002: STXBP1-DEE

IND clearance

ODD granted

Fast Track granted

CAP-003: PD-GBA

IND clearance

Human POC in Q4

Third clinical program in 2026

CAP-004: Friedreich’s ataxia

» Capsid engineering

» Cargo optimization

» Clinical development

» In-house manufacturing

» Protected by expansive IP portfolio

Strategic partnerships

abbvie » 1st AbbVie opt-in ($40M) achieved

Contract manufacturing

>$300M funding to date, including $50M Series A

32

Visuals: Three column cards with a thin teal outline and a blue-to-teal gradient header band. Left column holds three rounded pill shapes: blue (CAP-002) with three white check-circle icons, green (CAP-003) with one check-circle icon and a white bullet, and teal (CAP-004). Middle column has » chevron bullets. Right column has logo boxes with thin light-grey rounded borders: abbvie wordmark in dark blue with a » chevron beside it, Lilly red script logo, CRISPR Therapeutics black-framed logo, KATE Therapeutics (a Novartis company) logo with green/grey chevron mark. Bottom: Versant Ventures logo (teal V mark and grey text) and Westlake BioPartners logo (dark blue W mark, blue text) in white rounded boxes overlapping the right end of the grey bar. Thin teal horizontal line above the footer. Small Capsida Biotherapeutics logo bottom left.

Slide 33

Our Pipeline is Making the

Impossible Possible

[email protected]

1300 Rancho Conejo Blvd

Thousand Oaks, California

www.capsida.com

Visuals: Capsida Biotherapeutics logo at top left: 'CAPSIDA' in blue outlined geometric capitals, 'BIOTHERAPEUTICS' in grey letter-spaced capitals below it, and a blue-to-green faceted polyhedron/capsid shape with a small teal DNA strand curling over it. A large DNA double helix made of grey-blue dots (about #8FA9B8) spans the right 56% of the slide, running diagonally from top centre to bottom right, cropped at the edges. A thin light grey horizontal line runs across the lower left at about 70% of the slide height, ending at about 71% of the width. Three thin black outline icons: an envelope beside the email, a map pin beside the address, and a browser window with cursor beside the website.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview